Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT

Noor Ul Ain Rehman

Fri, Jul 11, 2025, 11:27 AM 2 min read

Viatris Inc. (NASDAQ:VTRS) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on June 30, Goldman Sachs reiterated a Hold rating on Viatris Inc. (NASDAQ:VTRS) with a price target of $10.00.

A healthcare worker in a lab coat, holding a microscope and reflecting on the diagnosis of a patient.

The company reported $3.3 billion in total revenues in fiscal Q1 2025, down 11% on a reported basis and down 2% on a divestiture-adjusted operational basis as compared to the same period last year. This drop was primarily attributed to the negative Indore Impact.

Management stated that if the Indore Impact is excluded, total revenues would have increased 2% on a divestiture-adjusted operational basis compared to fiscal Q1 2024.

Viatris Inc. (NASDAQ:VTRS) also generated around $67 million in new product revenues in fiscal Q1 2025, and expects to deliver new product revenues in 2025 in the $450 million to $550 million range.

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that provides healthcare and pharmaceutical products. The company’s medicines and treatments span various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women’s healthcare. Its operations are divided into the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.